🔎 Trials Near Me

Início › Câncer de Pulmão › Nebraska

Ensaios clínicos de Câncer de Pulmão em Nebraska

19 estudos para Câncer de Pulmão estão buscando participantes em locais em Nebraska.

Cidades em Nebraska

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Nebraska Medicine-Bellevue, Bellevue
  • Fred and Pamela Buffett Cancer Center - Kearney, Kearney
  • CHI Health Good Samaritan, Kearney
  • e mais 5
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • e mais 2
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Cancer Partners of Nebraska, Lincoln
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT04181060

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, LLC, Lincoln
  • NHO Support Center, Lincoln
  • Cancer Partners of Nebraska, Lincoln
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • Cancer Partners of Nebraska, Lincoln
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07489066

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
  • e mais 5
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06758401

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07063745

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Omaha
RecrutandoFase 2
Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06712316

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Nebraska Hematology-Oncology (NHO), Lincoln
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT06712355

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • Nebraska Methodist Hospital, Omaha
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05624996

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Nebraska Cancer Specialists, Omaha
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT04198766

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05242965

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Nebraska Cancer Specialist, Grand Island
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jun. de 2026 · NCT06162221

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • e mais 3
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
RecrutandoFase 2
Idades de 18 a 70 · Todos os sexos · Atualizado em 26 de jun. de 2026 · NCT04614103

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • Nebraska Cancer Specialists, Omaha
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de mai. de 2026 · NCT06922591

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.